H.R. 7658 — To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.

Summary

This bill reauthorizes through FY2027 the Food and Drug Administration's Critical Path Public-Private Partnerships, which support medical product innovation, development, and safety.

Full Text

Related Legislation

H.R. 7667Food and Drug Amendments of 2022
2022-06-09Received in the Senate.
Related
S. 4348FDASLA Act of 2022
2022-07-13Placed on Senate Legislative Calendar under General Orders. Calendar No. 444.
Related
S. 4152A bill to amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.
2022-05-05Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Related

Legislative Actions

2022-05-03
Introduced in House
2022-05-03
Introduced in House
2022-05-03
Referred to the House Committee on Energy and Commerce.

To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.

Sponsors

Subjects

Summary

Full Text

Related Legislation

Legislative Actions

Ask about this bill